The laboratory products and services company expects group organic growth of 8% to 11% a year from 2027.

Sartorius AG and its French-listed unit Sartorius Stedim Biotech set formal mid-term profitability targets on Tuesday, their ...

Sartorius Aktiengesellschaft (ETR:SRT) used its 2025 Capital Markets Day in Göttingen to outline strategic priorities, discuss midterm targets, and provide additional context on market conditions, ...

Shares in Sartorius rose on Tuesday after the German life sciences group set out a refined strategy focused on biopharmaceutical customers and unveiled new mid-term growth and profitability targets ...

(RTTNews) - Sartorius Stedim Biotech reported that its first half net profit increased to 154.1 million euros from 104.0 million euros, last year. Earnings per share was 1.58 euros compared to 1.08 ...

Sartorius Stedim Biotech, a subsidiary of Sartorius AG, is a leading provider of bioprocessing equipment and consumables. It offers a comprehensive portfolio that spans the full spectrum of upstream ...

Incoming Sartorius CEO Michael Grosse to become Chairman of the Board of Sartorius Stedim Biotech S.A. In its meeting, the Board of Directors of Sartorius Stedim Biotech S.A. (SSB) acknowledged the ...

Cleanroom space almost doubled, with automated production lines for single-use bags Automated logistics and warehouse platform to further increase delivery capability and speed Extended lab space for ...

Sartorius Stedim Biotech reported its first-quarter 2025 results, exceeding company-compiled consensus estimates. Sales and adjusted EBITDA increased in constant currency by 10.4% and 19.9%, ...

About Sartorius Stedim Biotech S.A. Sartorius Stedim Biotech SA provides equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry. The ...

Sartorius Stedim Biotech, a leading partner to the biopharmaceutical industry, and Nanotein Technologies, a developer of next-generation immune cell activation reagents, have entered into a ...

Sartorius Stedim Biotech, which reported 2025 sales revenue of around €3 billion, set a narrower organic growth target of 9% to 12% per year, with EBITDA margin expansion of 60 to 85 basis points ...